The median survival of patients with advanced or metastatic non-small-cell lung cancer (NSCLC) is only 10–11 months with either standard cisplatin-based chemotherapy [1], [2] or customized cisplatin-based chemotherapy based on excision repair cross-complementing 1 (ERCC1) mRNA expression,[3] and the two-year survival rate is only 14–21%.[1], [2], [3]. Here, ERCC1 is linked to non-small cell lung carcinoma.